Glucagon-like peptide 1 (GLP-1)

Research output: Contribution to journal › Review › Research › peer-review

Standard

Glucagon-like peptide 1 (GLP-1). / Mueller, T. D.; Finan, B.; Bloom, S. R.; D'Alessio, D.; Drucker, D. J.; Flatt, P. R.; Fritsche, A.; Gribble, F.; Grill, H. J.; Habener, J. F.; Holst, J. J.; Langhans, W.; Meier, J. J.; Nauck, M. A.; Perez-Tilve, D.; Pocai, A.; Reimann, F.; Sandoval, D. A.; Schwartz, T. W.; Seeley, R. J.; Stemmer, K.; Tang-Christensen, M.; Woods, S. C.; DiMarchi, R. D.; Tschoep, M. H.

In: Molecular Metabolism, Vol. 30, 2019, p. 72-130.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Mueller, TD, Finan, B, Bloom, SR, D'Alessio, D, Drucker, DJ, Flatt, PR, Fritsche, A, Gribble, F, Grill, HJ, Habener, JF, Holst, JJ, Langhans, W, Meier, JJ, Nauck, MA, Perez-Tilve, D, Pocai, A, Reimann, F, Sandoval, DA, Schwartz, TW, Seeley, RJ, Stemmer, K, Tang-Christensen, M, Woods, SC, DiMarchi, RD & Tschoep, MH 2019, 'Glucagon-like peptide 1 (GLP-1)', Molecular Metabolism, vol. 30, pp. 72-130. https://doi.org/10.1016/j.molmet.2019.09.010

APA

Mueller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., ... Tschoep, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. https://doi.org/10.1016/j.molmet.2019.09.010

Vancouver

Mueller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019;30:72-130. https://doi.org/10.1016/j.molmet.2019.09.010

Author

Mueller, T. D. ; Finan, B. ; Bloom, S. R. ; D'Alessio, D. ; Drucker, D. J. ; Flatt, P. R. ; Fritsche, A. ; Gribble, F. ; Grill, H. J. ; Habener, J. F. ; Holst, J. J. ; Langhans, W. ; Meier, J. J. ; Nauck, M. A. ; Perez-Tilve, D. ; Pocai, A. ; Reimann, F. ; Sandoval, D. A. ; Schwartz, T. W. ; Seeley, R. J. ; Stemmer, K. ; Tang-Christensen, M. ; Woods, S. C. ; DiMarchi, R. D. ; Tschoep, M. H. / Glucagon-like peptide 1 (GLP-1). In: Molecular Metabolism. 2019 ; Vol. 30. pp. 72-130.

Bibtex

@article{c564517f4564472192caa221d3bc16c1,

title = "Glucagon-like peptide 1 (GLP-1)",

abstract = "Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent beta-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders (C) 2019 The Authors. Published by Elsevier GmbH.",

keywords = "GLP-1, Insulin, Glucagon, Diabetes, Obesity",

author = "Mueller, {T. D.} and B. Finan and Bloom, {S. R.} and D. D'Alessio and Drucker, {D. J.} and Flatt, {P. R.} and A. Fritsche and F. Gribble and Grill, {H. J.} and Habener, {J. F.} and Holst, {J. J.} and W. Langhans and Meier, {J. J.} and Nauck, {M. A.} and D. Perez-Tilve and A. Pocai and F. Reimann and Sandoval, {D. A.} and Schwartz, {T. W.} and Seeley, {R. J.} and K. Stemmer and M. Tang-Christensen and Woods, {S. C.} and DiMarchi, {R. D.} and Tschoep, {M. H.}",

year = "2019",

doi = "10.1016/j.molmet.2019.09.010",

language = "English",

volume = "30",

pages = "72--130",

journal = "Molecular Metabolism",

issn = "2212-8778",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide 1 (GLP-1)

AU - Mueller, T. D.

AU - Finan, B.

AU - Bloom, S. R.

AU - D'Alessio, D.

AU - Drucker, D. J.

AU - Flatt, P. R.

AU - Fritsche, A.

AU - Gribble, F.

AU - Grill, H. J.

AU - Habener, J. F.

AU - Holst, J. J.

AU - Langhans, W.

AU - Meier, J. J.

AU - Nauck, M. A.

AU - Perez-Tilve, D.

AU - Pocai, A.

AU - Reimann, F.

AU - Sandoval, D. A.

AU - Schwartz, T. W.

AU - Seeley, R. J.

AU - Stemmer, K.

AU - Tang-Christensen, M.

AU - Woods, S. C.

AU - DiMarchi, R. D.

AU - Tschoep, M. H.

PY - 2019

Y1 - 2019

N2 - Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent beta-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders (C) 2019 The Authors. Published by Elsevier GmbH.

AB - Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent beta-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders (C) 2019 The Authors. Published by Elsevier GmbH.

KW - GLP-1

KW - Insulin

KW - Glucagon

KW - Diabetes

KW - Obesity

U2 - 10.1016/j.molmet.2019.09.010

DO - 10.1016/j.molmet.2019.09.010

M3 - Review

C2 - 31767182

VL - 30

SP - 72

EP - 130

JO - Molecular Metabolism

JF - Molecular Metabolism

SN - 2212-8778

ER -

ID: 232137365